Obesity: Difference between revisions

Revision as of 19:33, 14 October 2021

Semaglutide (Ozempic)
- GLP-1 analogue, so essentially sends a satiety signal
- Target dose of 2.4 mg/week (higher than for diabetes)
- In STEP 4 trial, lost 8% of body weight, with decreased waist circumference and blood pressure, up to 48 weeks
- GI side effects are common
- In the future, look out for combination treatment with GIP analogues
Bupropion/Naltrexone (Contrave)
- Bupropion stimuates POMC cells, suppressing appetits, and naltrexone blocks β-endorphin negative feedback loop which would otherwise prevent bupropion from having its intended effect
- About 30% of patients lost 10% body weight
Orlistat
- Poorly tolerated due to diarrhea
Bariatric surgery

@@ Line 7: / Line 7: @@
 === Pharmacotherapy ===
-* [[Semaglutide]] with target dose of 2.4 mg/week (higher than for diabetes)
+* [[Semaglutide]] (Ozempic)
+**GLP-1 analogue, so essentially sends a satiety signal
+**Target dose of 2.4 mg/week (higher than for diabetes)
 ** In STEP 4 trial, lost 8% of body weight, with decreased waist circumference and blood pressure, up to 48 weeks
 ** GI side effects are common
+**In the future, look out for combination treatment with GIP analogues
+*[[Bupropion]]/[[Naltrexone]] (Contrave)
+**Bupropion stimuates POMC cells, suppressing appetits, and naltrexone blocks β-endorphin negative feedback loop which would otherwise prevent bupropion from having its intended effect
+**About 30% of patients lost 10% body weight
+*[[Orlistat]]
+**Poorly tolerated due to diarrhea
+*Bariatric surgery